38 related articles for article (PubMed ID: 36841986)
1. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
[TBL] [Abstract][Full Text] [Related]
2. Accuracy and diagnostic performance of the Bethesda system for reporting thyroid cytopathology in a tertiary endocrine surgical referral center in Belgium.
Kinet S; Cornette H; Van Den Heede K; Brusselaers N; Van Slycke S
World J Surg; 2024 Feb; 48(2):386-392. PubMed ID: 38686788
[TBL] [Abstract][Full Text] [Related]
3. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.
Spaulding SL; Maayah M; Dinauer CA; Prasad M; Darbinyan A; Morotti R; Christison-Lagay ER
J Pediatr Surg; 2024 May; 59(5):975-980. PubMed ID: 38246817
[TBL] [Abstract][Full Text] [Related]
4. The Incidence of Thyroid Cancer in Bethesda III Thyroid Nodules: A Retrospective Analysis at a Single Endocrine Surgery Center.
Hassan I; Hassan L; Balalaa N; Askar M; Alshehhi H; Almarzooqi M
Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786324
[TBL] [Abstract][Full Text] [Related]
5. Radiofrequency ablation is an effective treatment for Bethesda III thyroid nodules without genetic alterations.
Fugazzola L; Deandrea M; Borgato S; Dell'Acqua M; Retta F; Mormile A; Carzaniga C; Gazzano G; Pogliaghi G; Muzza M; Persani L
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38657647
[TBL] [Abstract][Full Text] [Related]
6. Trends in Thyroid Nodules and Malignancy: A Two-Year Retrospective Study in a Tertiary Care Centre.
Guha R; Jana S; Biswas A; De KS; Das P
Indian J Otolaryngol Head Neck Surg; 2023 Jun; 75(2):713-719. PubMed ID: 37275012
[TBL] [Abstract][Full Text] [Related]
7. Molecular testing for thyroid nodules: Where are we now?
Ferraz C
Rev Endocr Metab Disord; 2024 Feb; 25(1):149-159. PubMed ID: 37902897
[TBL] [Abstract][Full Text] [Related]
8. Evolutionary analysis of indeterminate cytology and risk of malignancy in a thyroid nodule unit.
Alvarez-Mancha AI; Mancha-Doblas I; Molina-Vega M; Fernández-García D; Gómez-Pérez AM; Gallego E; Ortega-Jiménez MV; Hierro-Martín I; Tinahones FJ
Eur Thyroid J; 2024 May; ():. PubMed ID: 38743822
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of
Riccio IR; LaForteza AC; Hussein MH; Linhuber JP; Issa PP; Staav J; Fawzy MS; Toraih EA; Kandil E
EXCLI J; 2024; 23():283-299. PubMed ID: 38487090
[No Abstract] [Full Text] [Related]
10. High Malignancy Risk and Its Predictors in South Indian Patients With Bethesda II Thyroid Nodules.
Tirupati S; Puthenveetil P; Lakkundi S; Gaddam A; Sarathi V
Cureus; 2024 Feb; 16(2):e54923. PubMed ID: 38544601
[TBL] [Abstract][Full Text] [Related]
11. Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study.
Morand GB; Tessler I; Noik M; Krasner J; Yamin T; Pusztaszeri MP; Avior G; Payne RJ
Endocr Pract; 2024 Apr; 30(4):319-326. PubMed ID: 38184241
[TBL] [Abstract][Full Text] [Related]
12. Uni- and Multivariate Analyses of Cancer Risk in Cytologically Indeterminate Thyroid Nodules: A Single-Center Experience.
Battistella E; Mirabella M; Pomba L; Toniato R; Giacomini F; Magni G; Toniato A
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473241
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative thyroid frozen section: indications, results and consequences.
Gern J; Arbogast M; Alakus H; Brunner S; Schmidt M; Faust M; Bruns CJ; Schultheis AM; Chiapponi C
Gland Surg; 2024 May; 13(5):630-639. PubMed ID: 38845828
[TBL] [Abstract][Full Text] [Related]
14. The 3
Juhlin CC; Baloch ZW
Endocr Pathol; 2024 Mar; 35(1):77-79. PubMed ID: 38032439
[No Abstract] [Full Text] [Related]
15. Comments on "Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda category III in an endemic region".
Goel A; Kapatia G; Gupta S; Gupta V; Sidana S
Diagn Cytopathol; 2024 May; 52(5):288-289. PubMed ID: 38486129
[No Abstract] [Full Text] [Related]
16. Respond to "Comments on 'Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda category III in an endemic region'".
Aydın Kasap Z; Kurt B; Özsağır E; Ercin ME; Güner A
Diagn Cytopathol; 2024 May; 52(5):290-291. PubMed ID: 38504597
[No Abstract] [Full Text] [Related]
17. Rates of Malignancy in Cytology Indeterminate Thyroid Nodules: A Single Center Surgical Series.
Baraf L; Avidor Y; Bahat Dinur A; Yoel U; Samueli B; Joshua BZ; Fraenkel M
Isr Med Assoc J; 2023 Feb; 25(2):147-151. PubMed ID: 36841986
[TBL] [Abstract][Full Text] [Related]
18. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
19. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
